Agenus (NASDAQ:AGEN) Receives Neutral Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of Agenus (NASDAQ:AGEN) in a report released on Friday,Benzinga reports. The brokerage currently has a $7.00 price target on the biotechnology company’s stock.

Several other equities research analysts also recently issued reports on the stock. StockNews.com downgraded shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. B. Riley cut their price objective on Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $10.00.

Agenus Trading Down 2.0 %

NASDAQ AGEN opened at $3.42 on Friday. The firm has a market capitalization of $80.23 million, a P/E ratio of -0.30 and a beta of 1.39. The firm’s fifty day moving average price is $4.20 and its two-hundred day moving average price is $8.13. Agenus has a 1 year low of $2.50 and a 1 year high of $19.69.

Institutional Investors Weigh In On Agenus

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in Agenus by 13.7% during the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after acquiring an additional 4,134,232 shares during the period. Walleye Capital LLC bought a new position in shares of Agenus during the third quarter worth approximately $1,003,000. Price T Rowe Associates Inc. MD raised its position in shares of Agenus by 52.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 123,058 shares in the last quarter. Federated Hermes Inc. bought a new stake in shares of Agenus in the second quarter valued at approximately $1,921,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Agenus during the second quarter worth approximately $1,050,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.